报价延迟最少15分钟:2026/03/20 17:15 EDT
盘后时段
|
||||
|
-- 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.703
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.75/-0.50
|
|
企业价值
5.80M
|
| 资产负债 |
|
每股账面净值
1.14
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
7.29M
|
|
每股收益
0.15
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada. |
